
Charles River Laboratories International, Inc.
CRLNYSEHealthcareMedical - Diagnostics & Research
Previous close
$295.19
+$3.74 · +1.28%
CRL company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
5
Overpriced
Momentum
68
Gaining
Sentiment
65
Bullish
Risk resilience
61
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCharles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Birgit Girshick
- Listed since
- Jun 23, 2000
- Employees
- 19,000
Market position
Day range
Current $295.19
52-week range
Current $295.19
- Open
- $290.33
- Previous close
- $291.45
- Volume
- 757.76K
- 0.85× average
- Average volume
- 896.34K
- Average daily volume
- Market cap
- 14.22B USD
- Beta
- 1.38
- Market reference 1
- 50-day average
- $234.14
- +26.07% above average
- 200-day average
- $194.02
- +52.14% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 12.95B USD
- P/E (TTM)
- -60.99×
- P/B (TTM)
- 5.04×
- P/S (TTM)
- 3.56×
- EV / EBITDA
- 31.51×
- Earnings yield
- -1.43%
- Free cash flow yield
- 5.14%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 32.24%
- Operating margin
- 12.35%
- Net margin
- -5.96%
- Return on equity
- -4.56%
- Return on assets
- -2.02%
- Return on invested capital
- 8.36%
Financial health
- Debt / equity
- 1.07×
- Current ratio
- 1.29×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.02B USD | 4.05B USD | 4.13B USD | 3.98B USD | 3.54B USD |
| Cost of goods sold | 2.79B USD | 2.72B USD | 2.63B USD | 2.51B USD | 2.21B USD |
| Gross profit | 1.23B USD | 1.33B USD | 1.5B USD | 1.46B USD | 1.33B USD |
| Selling, general, and administrative | 743.07M USD | 751M USD | 747.86M USD | 665.1M USD | 619.92M USD |
| Operating expenses | 717.73M USD | 1.1B USD | 885.3M USD | 811.68M USD | 744.78M USD |
| Interest income | 4.94M USD | 8.58M USD | 5.2M USD | 780K USD | 652K USD |
| Interest expense | 107.03M USD | 126.29M USD | 136.71M USD | 59.29M USD | 73.91M USD |
| Depreciation and amortization | 403.31M USD | 361.74M USD | 314.12M USD | 303.87M USD | 265.54M USD |
| Operating income | 507.84M USD | 227.35M USD | 617.26M USD | 650.98M USD | 589.86M USD |
| Net income | −144.34M USD | 10.3M USD | 474.62M USD | 486.23M USD | 390.98M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 100%
- 11 beats, 0 misses, 0 met estimates
- Average EPS surprise
- +9.52%
- 11 comparable reports
- Latest EPS result
- 3.02
- Estimate 2.74 · Beat by 10.22%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$267.6
9.35% downsideCRL news
CRL peers
ETFs holding CRL
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI356.96M0.02%2.3T USD0.03%$378.24+0.44%
Vanguard S&P 500 ETFVOO293.94M0.02%1.7T USD0.03%$703.71+0.39%
Invesco S&P 500 Equal Weight ETFRSP292.12M0.29%100.27B USD0.20%$221.67+0.63%
Vanguard Morningstar Small-Cap ETFVB257.47M0.14%183.4B USD0.03%$304.76+0.64%
iShares Core S&P 500 ETFIVV189.22M0.02%891.84B USD0.03%$769.31+0.39%
State Street SPDR S&P 500 ETFSPY174.61M0.02%817.87B USD0.09%$765.72+0.41%
Vanguard Morningstar Small-Cap Value ETFVBR163.52M0.24%68.3B USD0.05%$249.18+0.68%
iShares Biotechnology ETFIBB103.72M0.98%10.75B USD0.44%$213.56+1.29%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 356.96M
- Weight
- 0.02%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard S&P 500 ETFVOO- Market value
- 293.94M
- Weight
- 0.02%
- AUM
- 1.7T USD
- Expense ratio
- 0.03%
- Price / 1D
- $703.71+0.39%
Invesco S&P 500 Equal Weight ETFRSP- Market value
- 292.12M
- Weight
- 0.29%
- AUM
- 100.27B USD
- Expense ratio
- 0.20%
- Price / 1D
- $221.67+0.63%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 257.47M
- Weight
- 0.14%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76+0.64%
iShares Core S&P 500 ETFIVV- Market value
- 189.22M
- Weight
- 0.02%
- AUM
- 891.84B USD
- Expense ratio
- 0.03%
- Price / 1D
- $769.31+0.39%
State Street SPDR S&P 500 ETFSPY- Market value
- 174.61M
- Weight
- 0.02%
- AUM
- 817.87B USD
- Expense ratio
- 0.09%
- Price / 1D
- $765.72+0.41%
Vanguard Morningstar Small-Cap Value ETFVBR- Market value
- 163.52M
- Weight
- 0.24%
- AUM
- 68.3B USD
- Expense ratio
- 0.05%
- Price / 1D
- $249.18+0.68%
iShares Biotechnology ETFIBB- Market value
- 103.72M
- Weight
- 0.98%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Continue in GoAI
Research CRLresearch.disclaimer











